title: Pharmacologic Therapies in Gastrointestinal Diseases.
abstract: Several key areas in gastroenterology pharmacotherapy are rapidly evolving, including the treatment of hepatitis C virus (HCV), irritable bowel syndrome, gastroesophageal reflux disease (GERD) and peptic ulcer disease. HCV treatment has radically changed in the past 2 years and now most patients are treatment candidates and have a high likelihood of permanent cure. Pharmacotherapy is now first-line treatment for patients with moderate to severe symptoms of irritable bowel syndrome. Proton pump inhibitors (PPIs) are the mainstay of therapy in gastric and duodenal ulcers and GERD, although long-term use carries the risk of several side effects that should be considered.
authors.affiliation: Division of General Internal Medicine, Department of Medicine, University of California, San Francisco School of Medicine, 1545 Divisadero St, Ste 307, San Francisco, CA, USA. Electronic address: rena.fox@ucsf.edu.
authors.forename: Rena K
authors.initials: RK
authors.lastname: Fox
authors.affiliation: Section of Digestive Diseases, Department of Medicine, Yale University School of Medicine, 333 Cedar Street, 1080 LMP, New Haven, CT 06520-8019, USA.
authors.forename: Thiruvengadam
authors.initials: T
authors.lastname: Muniraj
mesh_terms: D000863:Antacids / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D000930:Antidiarrheals / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D060085:Coinfection; D004043:Dietary Fiber; D024882:Drug Resistance, Viral; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000188:drug therapy*; D005838:Genotype; D015658:HIV Infections / Q000453:epidemiology; D016481:Helicobacter Infections / Q000188:drug therapy; D006526:Hepatitis C / Q000188:drug therapy* / Q000453:epidemiology; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy; D054368:Laxatives / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy; D019936:Probiotics / Q000627:therapeutic use; D054328:Proton Pump Inhibitors / Q000627:therapeutic use
chemical_list: D000863:Antacids; D000900:Anti-Bacterial Agents; D000928:Antidepressive Agents; D000930:Antidiarrheals; D000998:Antiviral Agents; D004043:Dietary Fiber; D005765:Gastrointestinal Agents; D006635:Histamine H2 Antagonists; D054368:Laxatives; D054328:Proton Pump Inhibitors
keywords: Direct acting antivirals; GERD; Hepatitis C virus; Irritable bowel syndrome; Peptic ulcer disease